CAMBRIDGE, Mass.--Hybridon, a genetically based drug discovery company here, has filed with the US Securities and Exchange Commission for a one-for-five reverse stock split, which would shrink the company's outstanding shares from about 25 million to 5 million. The plan, which will be presented to shareholders at a special meeting November 18, was proposed to help the company continue to meet Nasdaq listing requirements.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.